Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU

STOCKHOLM, Dec. 10, 2024 /PRNewswire/ — Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing followed by weekly maintenance dosing. The company’s focus going forward will be on the…